Molecular profiling of immune activation associated with regression of melanoma metastases induced by diphencyprone. Homo sapiens

The purpose of this study was to treat cutaneous melanoma metastases with topical DPCP, and then to comprehensively study the induced immune responses associated with tumor regression. Overall design: Six melanoma patients were sensitized to 0.4% DPCP on one of their cutaneous metastases and their right upper arm, as well on their left lower arm. Two weeks later, effective sensitization was confirmed by noting induration at the application sites, and then challenge applications were applied to the subject’s cutaneous metastases. Also at this visit, one 0.2 mL application of 0.4% DPCP was applied to one area of non-melanoma skin, and another 0.2 mL application of 0.04% DPCP was applied to a different area of non-melanoma skin. For all patients, one of the inflamed non-melanoma sites challenged with DPCP was biopsied 3 days later. All patients continued to receive their standard oncologic follow-up and monitoring visits.

本研究旨在采用外用二硝基氯苯（DPCP）治疗皮肤黑色素瘤转移灶，并全面探究与肿瘤消退相关的诱导免疫应答。研究整体设计：为6名黑色素瘤患者分别在其一处皮肤转移灶、右上臂及左下臂实施0.4%浓度的二硝基氯苯（DPCP）致敏。两周后，通过观察给药部位的硬结反应确认致敏成功，随后对患者的皮肤转移灶进行激发给药。本次随访期间，同时在一处非黑色素瘤皮肤区域涂抹0.2mL 0.4% DPCP，在另一处非黑色素瘤皮肤区域涂抹0.2mL 0.04% DPCP。所有患者均于激发给药后3天，对一处经DPCP处理的炎性非黑色素瘤部位完成活检。所有患者后续均接受标准肿瘤学随访与监测。